BIRC2 Antibodies

BIRC2 (Baculoviral IAP Repeat Containing 2) is a Protein Coding gene. Diseases associated with BIRC2 include Lung Cancer and Burkitt Lymphoma. Among its related pathways are Metabolism of proteins and Apoptosis and survival Caspase cascade. Gene Ontology (GO) annotations related to this gene include ligase activity and transcription coactivator activity. An important paralog of this gene is BIRC3.

CUSABIO produces high-quality anti-BIRC2 antibodies (includes polyclonal antibodies, monoclonal antibodies, recombinant antibodies) in house with strict quality control. And they can help you discover more in your research.
These BIRC2 antibodies are validated in multiple tissues with various applications and covering a broad range of life science research and drug development. They are featured with high specificity, multiple epitopes recognition, and wide species reactivity. Moreover, CUSABIO provides various options on sizes, excellent technical support and BIRC2 antibodies custom service.

BIRC2 Antibodies Catalog

BIRC2 Antibodies for Homo sapiens (Human)

BIRC2 Background

Baculoviral inhibitors of apoptosis repeat-containing protein 2 (BIRC2), also called cellular inhibitors of apoptosis 1 (cIAP1), is a protein in humans that is encoded by BIRC2 gene [1][2]. cIAP1 contains three tandem amino-terminal BIR domains, a zinc-binding RING domain at the carboxy terminus, and a caspase-recruitment (CARD) domain in the linker region between the BIR and the RING (Really Interesting New Gene) domains [3]. Among the domains of cIAP1, the RING domain exerts an important role in preventing apoptosis. This domain acts as an E3 ligase by binding to E2 ubiquitin-conjugating enzymes (UBCs) and catalyzing the transfer of ubiquitin onto target proteins [7] such as caspases, ultimately inhibiting apoptosis [3][4]. The CARD domain of cIAP1 is reported to emit a functional nuclear export signal that seems to be important for cell differentiation [12]. BIRC2 protein also mediates various cellular functions, including the regulation of signaling and inflammation [5]. Rothe M et al. have uncovered that BIRC2 and another IAP family member BIRC3, together with TRAF2, are key components of the TNF signaling pathway that are necessary for TNF-mediated NF-kappa B activation [6][7][8]. On the contrary, BIRC2, and BIRC3 act as a molecular brake to rein inactivation of the JNK signaling pathway [9]. The amplification and increased levels of cIAP1 have been observed in several cancer types and are required for tumorigenesis in vivo [10]. cIAP1 deprivation, caused by IAP antagonist drugs or cIAP1 deletion, might augment physiological TNF-receptor apoptotic signaling, thus resulting in enhanced tumor cell death [11]. It suggests a promising cancer treatment by using some IAP antagonist compounds [12].

[1] Liston P, Roy N, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes [J]. Nature. February 1996, 379 (6563): 349-53.
[2] Rothe M, Pan MG, et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins [J]. Cell. February 1996, 83 (7): 1243-52.
[3] Vaux D.L. & Silke J. IAPs, RINGs and ubiquitylation [J]. Nat. Rev. Mol. Cell Biol. 2005; 6: 287-297.
[4] Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination [J]. Proc. Natl Acad. Sci. USA 1999, 96, 11364-11369.
[5] Gyrd-Hansen M, Meier P IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer [J]. Nat Rev Cancer, 2010, 10:561-574.
[6] Rothe M, Pan MG, et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins [J]. Cell, 1995, 83:1243-1252.
[7] Mahoney DJ, Cheung HH, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation [J]. Proc Natl Acad Sci U S A, 2008, 105:11778-11783.
[8] Varfolomeev E, Goncharov T, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation [J]. J Biol Chem 2008, 283:24295-24299.
[9] B. M. Tan, N. W. Zammit, et al. Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor κB and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells [J]. Diabetologia volume 56, pages520-532 (2013).
[10] Zender L., Spector M.S., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach [J]. Cell. 2006; 125: 1253-1267.
[11] James E. Vince, W. Wei-Lynn Wong, et al. IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis [J]. VOLUME 131, ISSUE 4, P682-693, NOVEMBER 16, 2007.
[12] Plenchette S, Cathelin S, et al. Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event [J]. Blood, 2004, 104: 2035-2043.


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1